Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Down 52.8% in January

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a large decrease in short interest in January. As of January 31st, there was short interest totalling 57,800 shares, a decrease of 52.8% from the January 15th total of 122,400 shares. Based on an average daily volume of 620,100 shares, the short-interest ratio is presently 0.1 days. Currently, 0.2% of the shares of the company are sold short.

Achilles Therapeutics Trading Down 0.7 %

Achilles Therapeutics stock opened at $1.38 on Friday. Achilles Therapeutics has a 12 month low of $0.63 and a 12 month high of $1.76. The stock’s 50 day simple moving average is $1.16 and its two-hundred day simple moving average is $1.00. The firm has a market cap of $56.72 million, a PE ratio of -0.84 and a beta of 1.32.

Institutional Investors Weigh In On Achilles Therapeutics

An institutional investor recently bought a new position in Achilles Therapeutics stock. XTX Topco Ltd acquired a new position in Achilles Therapeutics plc (NASDAQ:ACHL) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 26,824 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned approximately 0.07% of Achilles Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 56.38% of the company’s stock.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.